Atossa Genetics Inc (NASDAQ:ATOS) investors are upbeat today upon news that this biotech player’s breast health program is getting an expansion. Specifically, the …
Following Phase 1 trial data for Atossa’s oral endoxifen, Maxim’s Jason Kolbert spotlights 208% in return potential for the stock.
Atossa Genetics is among the biotech stock movers in after-hours trading Thursday.
Maxim’s Jason Kolbert sheds light ahead of tomorrow’s Phase 1 oral endoxifen findings.
Analyst sees a bright future on the horizon.
Atossa Genetics may have taken a beating in the market yesterday after investors ran for the hills with fears of share dilution running …
Shares of breast cancer detection device maker Atossa Genetics Inc (NASDAQ:ATOS) are tumbling nearly 23%, as of this writing. The reason?
Shares of Atossa Genetics Inc (NASDAQ:ATOS) tumbled 43% in morning trade Thursday, after the healthcare company’s stock offering priced at a deep discount. The …
Today, Atossa Genetics Inc (NASDAQ:ATOS) investors are scratching their heads as to why the stock collapsed following the news that the company’s breast …
